Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
2001
Monitoring Ovarian Cancer with CA 125 During Chemotherapy
Sample size: 255
publication
Evidence: high
Author Information
Author(s): Tuxen M K, Sölétormos G, Dombernowsky P
Primary Institution: Department of Oncology, Herlev Hospital, University of Copenhagen
Hypothesis
Can CA 125 effectively monitor ovarian cancer patients during postoperative chemotherapy?
Conclusion
CA 125 is a reliable marker for predicting disease progression in ovarian cancer patients undergoing chemotherapy.
Supporting Evidence
- The efficiency of CA 125 for identifying progression and non-progression during first-line chemotherapy was 91.9%.
- The median lead time for true positive results was 41 days.
- Using a new criterion, the efficiency of CA 125 was 90.5% for identifying progression.
- The median lead time for true positive results with the new criterion was 35 days.
Takeaway
Doctors can use a blood test called CA 125 to see if ovarian cancer is getting worse during treatment.
Methodology
The study evaluated CA 125 levels in patients with stage IC-IV ovarian cancer during chemotherapy, using a new assessment criterion for monitoring.
Participant Demographics
Patients with stage IC-IV ovarian cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website